Surbhi Sidana, MD
Leads the Myeloma CAR-T program at Stanford University. Specializes in CAR-T cell therapy for myeloma.
Best podcasts with Surbhi Sidana, MD
Ranked by the Snipd community
Aug 3, 2023 • 7min
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Experts Salomon Manier, Surbhi Sidana, and Hermann Einsele discuss the optimal sequencing of bispecific antibodies and CAR-T cells in multiple myeloma, highlighting data from recent clinical trials. They explore mechanisms of resistance, factors to consider when sequencing, and potential sequencing strategies, recommending CAR-T cell therapy followed by bispecific antibodies based on emerging data.
